4.3 Review

Updates in treatment and impact of nail psoriasis

Related references

Note: Only part of the references are listed.
Article Dermatology

Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Luigi Gargiulo et al.

Summary: This retrospective study on 233 patients with moderate-to-severe plaque psoriasis who had an inadequate response to ustekinumab showed that guselkumab was more effective in achieving PASI 75/90/100 compared to ustekinumab.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

April W. Armstrong et al.

Summary: This study compared the efficacy and safety of deucravacitinib with placebo and apremilast in adults with moderate to severe plaque psoriasis. The results showed that deucravacitinib was more effective than placebo and apremilast in reducing symptoms and improving skin lesions, and the adverse event rates were similar among the three drugs.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)

Article Dermatology

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Bruce Strober et al.

Summary: This study aimed to compare the efficacy of Deucravacitinib with placebo and Apremilast in patients with moderate to severe plaque psoriasis. The results showed that at week 16, significantly more patients treated with Deucravacitinib achieved a reduction of 75% or more in the Psoriasis Area and Severity Index, as well as a static Physician's Global Assessment score of 0 or 1, compared to placebo and Apremilast. The efficacy of Deucravacitinib was maintained up to week 52.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)

Article Dermatology

Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial

Ulrich Mrowietz et al.

Summary: This study evaluated the efficacy and safety of apremilast in patients with plaque psoriasis in special areas and found that it significantly improved patients' quality of life, affected skin condition, and reduced itching and skin discomfort/pain.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

Intralesional steroid injections for inflammatory nail dystrophies in the pediatric population

Matilde Iorizzo et al.

Summary: Intralesional injections of triamcinolone acetonide are effective in treating inflammatory nail conditions in children and teenagers, even without a digital block. This technique should be considered as an alternative option for pediatric patients with inflammatory nail disorders, and clinicians should follow the step-by-step technique and pain reduction tips provided in this report.

PEDIATRIC DERMATOLOGY (2023)

Article Dermatology

Topical Tofacitinib as Effective Therapy in Patients with Plaque Psoriasis Responsive to Systemic Drugs but with Resistant Nail Psoriasis

Rachel Berbert Ferreira et al.

Summary: Psoriasis is a chronic inflammatory disease that may affect nails. Topical treatments are often limited in efficacy and may cause side effects or lack of compliance. Intralesional treatment is often unwanted by patients. Therefore, new therapies for nail psoriasis are needed.

SKIN APPENDAGE DISORDERS (2023)

Article Dermatology

A pilot study of intralesional methotrexate injections versus triamcinolone acetonide in patients affected by nail matrix psoriasis

Michela Starace et al.

Summary: This study aimed to compare the treatment response of nail matrix psoriasis patients who received different medication injections. The results showed that all patients experienced improvement in their condition during treatment, with the MTX-treated group showing significant improvement.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

Article Microbiology

Fungal Infections and Nail Psoriasis: An Update

Aikaterini Kyriakou et al.

Summary: The relationship between psoriasis and onychomycosis is still controversial, but nail involvement and abnormal blood vessels in psoriasis may weaken the natural defense against fungal infection. Treatment with immunosuppressive drugs may also increase the risk of onychomycosis.

JOURNAL OF FUNGI (2022)

Article Medicine, General & Internal

Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis

Marco Galluzzo et al.

Summary: This retrospective analysis provides evidence that Tildrakizumab is an effective and safe option for managing psoriasis in difficult-to-treat locations, showing significant improvements in disease severity and treatment response.

JOURNAL OF CLINICAL MEDICINE (2022)

Review Dermatology

Deucravacitinib for the Treatment of Psoriatic Disease

Ana Maria Le et al.

Summary: Deucravacitinib is a new oral drug that selectively inhibits TYK2, showing good efficacy and safety in the treatment of psoriasis. It provides significant improvement in symptoms, particularly itch, and has persistent efficacy for up to 2 years. It offers several advantages as an oral, effective, and safe treatment option for psoriasis.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)

Article Dermatology

One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial

Bruce Strober et al.

Summary: Tapinarof cream 1% demonstrated long-term safety, efficacy, and durability in the treatment of plaque psoriasis, with a high rate of disease clearance and remittive effect.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Letter Dermatology

How to choose a systemic treatment for moderate-to-severe nail psoriasis

D. Rigopoulos et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Article Dermatology

Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3

Alexander Egeberg et al.

Summary: This study evaluates the long-term effects of ixekizumab treatment on nail psoriasis, showing that continuous treatment can improve and clear nail psoriasis regardless of the severity at baseline.

ACTA DERMATO-VENEREOLOGICA (2022)

Article Dermatology

Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis

Giuseppe Gallo et al.

Summary: Topical cyclosporine hydrogel ointment has shown efficacy and safety in the treatment of nail psoriasis, being easy to apply and well-tolerated by patients.

DERMATOLOGIC THERAPY (2022)

Article Medicine, General & Internal

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis The DERMIS-1 and DERMIS-2 Randomized Clinical Trials

Mark G. Lebwohl et al.

Summary: Treatment with 0.3% roflumilast cream once daily for 8 weeks showed better clinical outcomes compared to vehicle cream in patients with chronic plaque psoriasis. Further research is required to compare efficacy with other active treatments and assess long-term efficacy and safety.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Review Dermatology

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge

Angelo Ruggiero et al.

Summary: Bimekizumab, a novel antibody, shows promising results in the treatment of moderate to severe psoriasis. It has demonstrated high efficacy and safety in multiple clinical trials, achieving PASI90 and PASI100 in a short time and maintaining it in the long term. Compared to other drugs, Bimekizumab has a faster onset of response and higher efficacy.

PSORIASIS-TARGETS AND THERAPY (2022)

Letter Dermatology

Treatment of nail psoriasis with intramatrical methotrexate: An uncontrolled prospective study of 20 patients

Paras Choudhary et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Article Dermatology

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study

K. Reich et al.

Summary: Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2 center dot 5 years in nail psoriasis, with significant sustained quality-of-life improvements and a favorable safety profile. No new safety findings were observed, indicating the long-term safety of Secukinumab in treating nail psoriasis.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Review Dermatology

Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis

I-Hsin Huang et al.

Summary: The network meta-analysis revealed that tofacitinib and ixekizumab showed the best efficacy in treating nail psoriasis, with ixekizumab demonstrating the most improvement in 100% of NAPSI.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Review Rheumatology

Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs

Gurjit S. Kaeley et al.

Summary: This review article discusses the advances in diagnostic techniques and treatment options for psoriatic nail disease, emphasizing the association between NP and PsA. The importance of accurately diagnosing and treating NP to prevent nail damage and delay the onset of joint disease is highlighted. Further research is needed to improve the management of PsD due to the lack of standardized NP scoring systems and well-defined treatment guidelines.

JOURNAL OF RHEUMATOLOGY (2021)

Article Dermatology

Successful management of treatment resistant nail psoriasis with tildrakizumab

Kate Simpson et al.

Summary: Tildrakizumab has shown significant improvement in treating treatment resistant nail psoriasis with no observed side effects. This medication presents a promising option in managing patients with this type of psoriasis.

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2021)

Letter Dermatology

Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy

A. Egeberg et al.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Review Dermatology

The promise and challenges of cell therapy for psoriasis

S. M. Lwin et al.

Summary: Biological therapies have transformed the management of moderate-to-severe psoriasis, but for patients who do not respond, cell therapy may be a new option. Well-designed trials and mechanistic studies are needed for the development and delivery of advanced cell therapies for severe psoriasis.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Article Dermatology

Development and validation of the Physician's Global Assessment of Fingernail Psoriasis

S. Hudgens et al.

Summary: The study developed a new clinician-rated severity scale, PGA-F, which showed good content validity and measurement consistency through cognitive interviews and experimental validation. It can rapidly and accurately assess the severity of nail psoriasis.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Article Dermatology

Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial

Luis Puig et al.

Summary: The study demonstrated that treatment with NTK resulted in a significant reduction of symptoms in patients with moderate-to-severe plaque psoriasis, with a good safety profile and low immunogenicity. Long-term efficacy and safety data from the ongoing study are anticipated.

DERMATOLOGY AND THERAPY (2021)

Review Dermatology

The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review

Claire R. Stewart et al.

Summary: Nail involvement is common in psoriasis patients, affecting at least 80% of individuals. Studies show that patients with nail psoriasis have higher disease severity and poorer quality of life compared to those without nail involvement, emphasizing the need for prompt treatment and focus on improving QoL outcomes.

SKIN APPENDAGE DISORDERS (2021)

Letter Dermatology

Nail psoriasis treated with intralesional methotrexate infiltration

Artur Antonio Duarte et al.

ANAIS BRASILEIROS DE DERMATOLOGIA (2019)

Review Dermatology

Reporting of outcomes in randomized controlled trials on nail psoriasis: a systematic review

C. I. Busard et al.

BRITISH JOURNAL OF DERMATOLOGY (2018)

Article Dermatology

Intramatricial injections for nail psoriasis: An open-label comparative study of triamcinolone, methotrexate, and cyclosporine

Jyotisterna Mittal et al.

INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2018)

Article Dermatology

Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study

Craig Leonardi et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

Review Pharmacology & Pharmacy

Tofacitinib: A New Oral Therapy for Psoriasis

Alexandra Azevedo et al.

CLINICAL DRUG INVESTIGATION (2018)

Article Dermatology

A Case of Nail Psoriasis Successfully Treated with Intralesional Methotrexate

Sana Mokni et al.

DERMATOLOGY AND THERAPY (2018)

Article Dermatology

Identification of nail features associated with psoriasis severity

Jee Woong Choi et al.

JOURNAL OF DERMATOLOGY (2017)

Letter Dermatology

Pulsed dye laser in the treatment of psoriatic nails: a controlled study

N. Y. Youssef et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)

Review Dermatology

Onychomycosis in patients with nail psoriasis: a point to point discussion

Dimitrios Rigopoulos et al.

MYCOSES (2017)

Article Dermatology

Nail findings in patients with psoriatic arthritis: A cross-sectional study with special reference to transverse grooves

Yukari Zenke et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

Article Health Care Sciences & Services

Patient-relevant needs and treatment goals in nail psoriasis

C. Blome et al.

QUALITY OF LIFE RESEARCH (2016)

Letter Dermatology

Intralesional Injection for Inflammatory Nail Diseases

Ashlynne Clark et al.

DERMATOLOGIC SURGERY (2016)

Review Dermatology

Laser and light therapies for the treatment of nail psoriasis

Eric L. Maranda et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)

Article Dermatology

Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis

A. Langenbruch et al.

BRITISH JOURNAL OF DERMATOLOGY (2014)

Article Dermatology

Proximal nail fold intralesional steroid injection responsible for Hoigne syndrome

R. Baran

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)

Article Dermatology

Nail Psoriasis, the unknown burden of disease

K. M. G. Klaassen et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)

Letter Dermatology

Quality of life and severity of skin and nail involvement in patients with plaque psoriasis

Aikaterini Kyriakou et al.

EUROPEAN JOURNAL OF DERMATOLOGY (2014)

Review Dermatology

Health-Related Quality of Life in Patients with Nail Disorders

Adam Reich et al.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2011)

Article Dermatology

Nail Psoriasis Successfully Treated with Intralesional Methotrexate: Case Report

Hayriye Saricaoglu et al.

DERMATOLOGY (2011)

Article Dermatology

Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy)

M. Sanchez-Regana et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2011)

Article Dermatology

Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study

M. Gumusel et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2011)

Article Dermatology

Nail psoriasis in Germany: epidemiology and burden of disease

M. Augustin et al.

BRITISH JOURNAL OF DERMATOLOGY (2010)

Article Dermatology

Development and validation of nail psoriasis quality of life scale (NPQ10)

J. P. Ortonne et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2010)

Article

Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis

Antonella Tosti et al.

ARCHIVES OF DERMATOLOGY (2009)

Article Dermatology

Association of patient-reported psoriasis severity with income and employment

Elizabeth J. Horn et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)

Article Dermatology

Interobserver reliability of the Nail Psoriasis Severity Index

S. Aktan et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2007)

Letter Dermatology

Modification of the nail psoriasis severity index

CA Parrish et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)

Article Dermatology

Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis

P Rich et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)